CareLit Fachartikel

Effect of anti-acid medication on reduction in FVC decline with nintedanib

U Costabel, B Crestani, Z Bailes, R Schlenker-Herceg, G Raghu · Pneumologie · 2016 · Heft 02

Dokument
1145826
CareLit-ID
Jahr
2016
Publikation
PDF
nein
Metadaten
DOI
ja
zitierfähig

Bibliografische Angaben

Zeitschrift
Pneumologie
Autor:innen
U Costabel, B Crestani, Z Bailes, R Schlenker-Herceg, G Raghu
Ausgabe
Heft 02 / 2016
Seiten
–
Erschienen: 2016-02-09 00:00:00
ISSN
0934-8387
DOI
10.1055/s-0036-1571998

Zusammenfassung

Background: It has been suggested that anti-acid medication may impact the progression of idiopathic pulmonary fibrosis (IPF). The two replicate, 52-week, Phase III INPULSIS® trials assessed the efficacy of nintedanib 150 mg twice daily (bid) in patients with IPF. In both trials, nintedanib significantly reduced the annual rate of decline in forced vital capacity (FVC), the primary endpoint, vs. placebo. Aim: To assess whether use of anti-acid medication at baseline influenced the treatment effect of nintedanib. Methods: A post-hoc analysis of patients receiving vs. not receiving anti-acid medication (proton pum…

Schlagworte

Anti-Acid Medication Patients Nintedanib Receiving Baseline Trials Placebo Decline Inpulsis Effect Annual Pneumologie